The potential of biguanides, alpha-glucosidase inhibitors, DPP-4inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists as anti-obesity medications were highlighted in this study’s evaluation of many clinical trials that looked at antihyperglycemic treatments that have demonstrated weight loss effects. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.